큐라클

365270KOSDAQ자연과학 및 공학 연구개발업

46.8 / 100

Reference Date: 2026-07-24

Financial Score9.5 / 40

News Sentiment21.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR raises overvaluation concerns, Revenue is on a declining trend. Plunged 26.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Curacle is a biotech venture company developing innovative therapeutics targeting endothelial dysfunction, leveraging its proprietary platforms Solvadys and Eagles to advance first-in-class drug candidates such as CU06, CU71, and CU01. CU06, a retinal disease treatment, demonstrated vision improvement in Phase 2a trials, while collaborations with MapTics have expanded its antibody-based pipeline.

Number of Employees

31people

Average Salary

81.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

5.38Industry Average 2.520.0Point

2.1x industry avg (risky)

ROE

-54.03Industry Average -32.093.5Point

1.7x industry avg (good)

Debt Ratio

9.08Industry Average 7.312.0Point

Higher than industry avg (caution)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼91.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼25.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -40.6% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
생명연, 딥테크 바이오 사업화 ‘잭팟’ 비결…글로벌 기술이전 잇따...
생명연의 바이오 창업 및 사업화 전략이 성공적으로 입증되어 큐라클에 긍정적 영향을 미치고 있다.
Positive
큐라클-맵틱스, 차세대 항혈전 신약 'MT-201' 국가신약개발사업 선...
큐라클의 차세대 항혈전 신약 MT-201이 국가신약개발사업 신규 과제로 선정되어 긍정적인 시장 반응을 보임.
Positive
큐라클, 에임블과 AI 신약개발 맞손...혈관질환 신약 발굴 속도 높인...
큐라클과 에임블의 AI 협력으로 혈관질환 신약 개발 속도가 가속화되어 긍정적인 전망을 제공합니다.

Detailed Momentum

52-week position3.0Point

52w lower range (33%)

Current 9,000Won52-week high 19,71052-week low 3,650

1-month return0.0Point

1m -26.53% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0